Obviously, low MCL1-M MM had significantly lower IC50 values for doxorubicin than those in high MCL1-M MM, indicating that patients in the low-risk MCL1-M group were more sensitive to doxorubicin. This evidence concerns the gene MCL1 and Miyoshi myopathy.